Cargando…

Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria

Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oehadian, Amaylia, Santoso, Prayudi, Menzies, Dick, Ruslami, Rovina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987663/ https://www.ncbi.nlm.nih.gov/pubmed/35045688 http://dx.doi.org/10.4046/trd.2021.0122

Ejemplares similares

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
por: Oehadian, Amaylia, et al.
Publicado: (2022)

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters
por: Annisa, Nurul, et al.
Publicado: (2022)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Analytical and Clinical Validation of Assays for Volumetric Absorptive Microsampling (VAMS) of Drugs in Different Blood Matrices: A Literature Review
por: Nugraha, Rhea Veda, et al.
Publicado: (2023)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study
por: Soeroto, Arto Yuwono, et al.
Publicado: (2021)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
por: Yuan, Yuan, et al.
Publicado: (2022)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
por: Azimi, Taher, et al.
Publicado: (2022)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

The detection of Howell-Jolly body-like inclusions in a case of coronavirus disease-2019 (COVID-19)
por: Alisjahbana, Bachti, et al.
Publicado: (2020)

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis
por: Agyeman, Akosua Adom, et al.
Publicado: (2016)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Intrathecal/Intraventricular Linezolid in Multidrug-Resistant Enterococcus faecalis Ventriculitis
por: Lich, Brian F., et al.
Publicado: (2016)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis
por: Song, Taeksun, et al.
Publicado: (2015)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Linezolid for drug‐resistant pulmonary tuberculosis
por: Singh, Bhagteshwar, et al.
Publicado: (2019)

Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus
por: Negatu, Dereje A., et al.
Publicado: (2023)

Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy
por: Ausi, Yudisia, et al.
Publicado: (2021)

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
por: Eker, Barbara, et al.
Publicado: (2008)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis
por: Li, Yuan, et al.
Publicado: (2019)

Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018
por: McDowell, Ashley, et al.
Publicado: (2020)

Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report
por: Lee, Jaemin, et al.
Publicado: (2021)

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2017)

Howell-Jolly Body-Like Inclusions in Coronavirus Disease 2019 (COVID-19): Possible Novel Findings
por: Oehadian, Amaylia, et al.
Publicado: (2023)

Linezolid Resistance in Staphylococci
por: Stefani, Stefania, et al.
Publicado: (2010)

Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India
por: Tornheim, J.A., et al.
Publicado: (2020)

Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance
por: Gawryszewska, I., et al.
Publicado: (2017)

Clonal Expansion of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, Japan
por: Murase, Yoshiro, et al.
Publicado: (2010)

Linezolid- and Multidrug-Resistant Enterococci in Raw Commercial Dog Food, Europe, 2019–2020
por: Freitas, Ana R., et al.
Publicado: (2021)

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
por: Lange, Christoph, et al.
Publicado: (2014)

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis
por: Huang, Ian, et al.
Publicado: (2020)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9dh1e6e5k9n7rgbr431qihfo5p